-
公开(公告)号:US20070219140A1
公开(公告)日:2007-09-20
申请号:US11607964
申请日:2006-12-04
申请人: Alain Laurent , Kim Hewitt , Stephen Morris , Patrick Bureau , Alain Boudreault , Scott Jarvis , James Jaquith
发明人: Alain Laurent , Kim Hewitt , Stephen Morris , Patrick Bureau , Alain Boudreault , Scott Jarvis , James Jaquith
IPC分类号: A61K38/06 , A61K38/05 , A61K38/04 , C07K5/08 , C07K5/06 , C07D403/14 , A61K31/4025
CPC分类号: C07D207/16 , A61K38/00 , C07D403/06 , C07D403/14 , C07K5/0806
摘要: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1 are substitutents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.
摘要翻译: 公开了由式I表示的化合物或其盐的异构体,对映异构体,非对映异构体或互变异构体,其中R 1,R 2,R 100, A,A,B,B,B,B,B,B,B,B,B, SUP>是描述的替代品。 还公开了使用式1的化合物来治疗增殖性疾病。
-
公开(公告)号:US07795298B2
公开(公告)日:2010-09-14
申请号:US11607998
申请日:2006-12-04
申请人: Alain Laurent , Kim Hewitt , Stephen Morris , Patrick Bureau , Alain Boudreault , Scott Jarvis , James Jaquith
发明人: Alain Laurent , Kim Hewitt , Stephen Morris , Patrick Bureau , Alain Boudreault , Scott Jarvis , James Jaquith
IPC分类号: A61K31/40 , C07D207/06
CPC分类号: C07D207/16 , A61K38/00 , C07D403/06 , C07D403/14 , C07K5/0806
摘要: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1 are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.
摘要翻译: 公开了由式I表示的化合物或其盐的异构体,对映异构体,非对映异构体或互变异构体,其中R1,R2,R100,R200,A,A1,B,B1,BG,n,Q和Q1是取代基 描述。 还公开了使用式1的化合物来治疗增殖性疾病。
-
公开(公告)号:US20070093429A1
公开(公告)日:2007-04-26
申请号:US11607998
申请日:2006-12-04
申请人: Alain Laurent , Kim Hewitt , Stephen Morris , Patrick Bureau , Alain Boudreault , Scott Jarvis , James Jaquith
发明人: Alain Laurent , Kim Hewitt , Stephen Morris , Patrick Bureau , Alain Boudreault , Scott Jarvis , James Jaquith
IPC分类号: A61K38/06 , A61K31/4025
CPC分类号: C07D207/16 , A61K38/00 , C07D403/06 , C07D403/14 , C07K5/0806
摘要: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1 are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.
-
公开(公告)号:US08063095B2
公开(公告)日:2011-11-22
申请号:US11607964
申请日:2006-12-04
申请人: Alain Laurent , Kim Hewitt , Stephen Morris , Patrick Bureau , Alain Boudreault , Scott Jarvis , James Jaquith
发明人: Alain Laurent , Kim Hewitt , Stephen Morris , Patrick Bureau , Alain Boudreault , Scott Jarvis , James Jaquith
IPC分类号: A61K31/4025 , C07D207/09
CPC分类号: C07D207/16 , A61K38/00 , C07D403/06 , C07D403/14 , C07K5/0806
摘要: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1 are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.
摘要翻译: 公开了由式I表示的化合物或其盐的异构体,对映异构体,非对映异构体或互变异构体,其中R1,R2,R100,R200,A,A1,B,B1,BG,n,Q和Q1是取代基 描述。 还公开了使用式1的化合物来治疗增殖性疾病。
-
公开(公告)号:US20080014207A1
公开(公告)日:2008-01-17
申请号:US11606883
申请日:2006-12-01
申请人: Alain Laurent , Kim Hewitt , Stephen Morris , Patrick Bureau , Alain Boudreault , Scott Jarvis , James Jaquith
发明人: Alain Laurent , Kim Hewitt , Stephen Morris , Patrick Bureau , Alain Boudreault , Scott Jarvis , James Jaquith
IPC分类号: A61K39/395 , A61K31/4025 , A61P35/00 , C07D207/09
CPC分类号: C07D207/16 , A61K38/00 , C07D403/06 , C07D403/14 , C07K5/0806
摘要: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1 are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.
摘要翻译: 公开了由式I表示的化合物或其盐的异构体,对映异构体,非对映异构体或互变异构体,其中R 1,R 2,R 100, A,A,B,B,B,B,B,B,B,B,B, SUP>是描述的取代基。 还公开了使用式1的化合物来治疗增殖性疾病。
-
公开(公告)号:US07547724B2
公开(公告)日:2009-06-16
申请号:US11606883
申请日:2006-12-01
申请人: Alain Laurent , Kim E. Hewitt , Stephen Morris , Patrick Bureau , Alain Boudreault , Scott Jarvis , James Jaquith
发明人: Alain Laurent , Kim E. Hewitt , Stephen Morris , Patrick Bureau , Alain Boudreault , Scott Jarvis , James Jaquith
IPC分类号: A61K31/427 , C07D417/04
CPC分类号: C07D207/16 , A61K38/00 , C07D403/06 , C07D403/14 , C07K5/0806
摘要: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1 are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.
-
公开(公告)号:US08163792B2
公开(公告)日:2012-04-24
申请号:US12301213
申请日:2007-05-16
申请人: Alain Laurent , Scott Jarvis , Patrick Bureau , Alain Boudreault , James Jaquith
发明人: Alain Laurent , Scott Jarvis , Patrick Bureau , Alain Boudreault , James Jaquith
IPC分类号: C07D207/09 , A61K31/4025
CPC分类号: G01N33/57484 , C07D207/09 , C07D207/16 , C07D401/14 , C07D403/14 , C07D409/14 , C07D487/06 , C07D493/10 , C07K5/022 , C07K5/06026 , C07K5/06191 , G01N2333/4703 , G01N2333/70596 , G01N2500/02
摘要: Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.
摘要翻译: 本文公开了由式I表示的化合物的异构体,对映异构体,非对映异构体或互变异构体:或前药或药学上可接受的盐,或用可检测标记或其亲和标签标记; 其中R1,R1a,R100,R100a,R2,R200,W,B和W1在本文中定义。 还公开了使用式I化合物治疗增殖性疾病如癌症的方法。
-
公开(公告)号:US20060264379A1
公开(公告)日:2006-11-23
申请号:US11434166
申请日:2006-05-16
申请人: Scott Jarvis , Alain Boudreault , Patrick Bureau , James Jaquith , Alain Laurent , Delphine Labit
发明人: Scott Jarvis , Alain Boudreault , Patrick Bureau , James Jaquith , Alain Laurent , Delphine Labit
CPC分类号: C07D207/09 , C07K5/06026 , C07K5/06034 , C07K5/06069
摘要: The present invention is directed towards an isomer, an enantiomer, a diastereoisomer, or a tautomer of a pyrrolidine compound represented by Formula I: in which the substituents R1, R1a, R2, R2a, R3, A and Q are defined herein; or a prodrug, or a salt thereof, and which bind to IAP BIR domains. In particular, the compounds are useful in treating proliferative disorders such as cancer
摘要翻译: 本发明涉及由式I表示的吡咯烷化合物的异构体,对映体,非对映异构体或互变异构体:其中取代基R 1,R 1a, R 2,R 2,R 3,A和Q在本文中定义; 或其前药或其盐,并且其结合IAP BIR结构域。 特别地,这些化合物可用于治疗增殖性疾病如癌症
-
公开(公告)号:US20120195915A1
公开(公告)日:2012-08-02
申请号:US13425542
申请日:2012-03-21
申请人: Alain Laurent , Scott Jarvis , Patrick Bureau , Alain Boudreault , James Jaquith
发明人: Alain Laurent , Scott Jarvis , Patrick Bureau , Alain Boudreault , James Jaquith
CPC分类号: G01N33/57484 , C07D207/09 , C07D207/16 , C07D401/14 , C07D403/14 , C07D409/14 , C07D487/06 , C07D493/10 , C07K5/022 , C07K5/06026 , C07K5/06191 , G01N2333/4703 , G01N2333/70596 , G01N2500/02
摘要: Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.
-
公开(公告)号:US08648094B2
公开(公告)日:2014-02-11
申请号:US13425542
申请日:2012-03-21
申请人: Alain Laurent , Scott Jarvis , Patrick Bureau , Alain Boudreault , James Jaquith
发明人: Alain Laurent , Scott Jarvis , Patrick Bureau , Alain Boudreault , James Jaquith
IPC分类号: A61K31/4025 , A61K31/444 , C07D401/12 , C07D403/12
CPC分类号: G01N33/57484 , C07D207/09 , C07D207/16 , C07D401/14 , C07D403/14 , C07D409/14 , C07D487/06 , C07D493/10 , C07K5/022 , C07K5/06026 , C07K5/06191 , G01N2333/4703 , G01N2333/70596 , G01N2500/02
摘要: Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.
摘要翻译: 本文公开了由式I表示的化合物的异构体,对映异构体,非对映异构体或互变异构体:或前药或药学上可接受的盐,或用可检测标记或其亲和标签标记; 其中R1,R1a,R100,R100a,R2,R200,W,B和W1在本文中定义。 还公开了使用式I化合物治疗增殖性疾病如癌症的方法。
-
-
-
-
-
-
-
-
-